当前位置： SCI文献检索 > VACCINE期刊下所有文献 > The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.

The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.

Abstract：

:Equine influenza is a contagious diseases caused by equine influenza viruses which belong to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently competition horses are required to be regularly vaccinated against equine influenza. Currently available inactivated vaccines are only able to induce protection against clinical disease and virus excretion after a primary vaccination course consisting of three vaccine applications at 4-6 and 22-26 weeks apart, respectively. It has been suggested that these vaccines induce no adequate protection in horses at 22-26 weeks (5 months) in the primary vaccination course (immediately prior to the last booster), despite various alternative vaccination regimens proposed. In this paper we describe the efficacy and safety profile, tested in an experimental setting according to European legislation of a novel inactivated equine influenza vaccine formulation (Prequenza). This formulation consists besides influenza antigen, of second generation ISCOM-Matrix as an adjuvant. The vaccine aims at the induction of protection from the onset of immunity, i.e. after the first two vaccine applications, until the first booster given 5 months later, against challenge with a virulent equine influenza strain. The protection against A/equine/Kentucky/95 (H3N8) was evidenced by a reduction of clinical signs of influenza, a reduction of virus excretion and a reduction of fever. The vaccine was shown to be safe in pregnant mares, foals and is used safely since 2 years as a commercial vaccine in Europe.

journal_name

Vaccine

journal_title

Vaccine

authors

Heldens JG,Pouwels HG,Derks CG,Van de Zande SM,Hoeijmakers MJ

doi

10.1016/j.vaccine.2009.06.085

subject

Has Abstract

pub_date

2009-09-04 00:00:00

pages

5530-7

issue

40

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(09)00959-1

journal_volume

27

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

    abstract：:Immune responses to poorly immunogenic antigens, such as polysaccharides, can be enhanced by conjugation to carriers. Our previous studies indicate that conjugation to Vi polysaccharide of Salmonella Typhi may also enhance immunogenicity of some protein carriers. We therefore explored the possibility of generating a b...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.04.035

    authors： An SJ,Scaria PV,Chen B,Barnafo E,Muratova O,Anderson C,Lambert L,Chae MH,Yang JS,Duffy PE

    更新日期：2018-05-17 00:00:00

  • Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).

    abstract：:The hepatitis E virus (HEV) vaccine, Hecolin(®), was licensed in China for the prevention of HEV infection and HEV-related diseases with demonstrated safety and efficacy [1,2]. The vaccine is composed of a truncated HEV capsid protein, p239, as the sole antigen encoded by open reading frame 2 and produced using Escher...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.05.064

    authors： Zhang X,Wei M,Pan H,Lin Z,Wang K,Weng Z,Zhu Y,Xin L,Zhang J,Li S,Xia N,Zhao Q

    更新日期：2014-07-07 00:00:00

  • Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin.

    abstract：:Anti-angiogenesis represents an indispensible strategy for cancer therapy. As a strictly endothelial-specific adhesion molecule, vascular endothelial cadherin (VE-cadherin, VE-cad) is a promising anti-angiogenesis target. In this study a recombinant adenovirus vector modified with mannan was used to deliver VE-cad (Ad...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.03.109

    authors： Zhao Z,Yao Y,Ding Z,Chen X,Xie K,Luo Y,Zhang J,Chen X,Wu X,Xu J,Zhao J,Niu T,Liu J,Li Q,Zhang W,Wen Y,Su J,Hu B,Bu H,Wei Y,Wu Y

    更新日期：2011-06-06 00:00:00

  • Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.

    abstract：:A recombinant Plasmodium falciparum circumsporozoite (CS) antigen (rPfCSA) was produced in insect cells using a baculovirus expression vector containing the entire CS gene. This near full-length CS antigen was adsorbed onto aluminium phosphate for use as a malaria vaccine. In a study of safety and immunogenicity, 20 v...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(92)90047-n

    authors： Herrington DA,Losonsky GA,Smith G,Volvovitz F,Cochran M,Jackson K,Hoffman SL,Gordon DM,Levine MM,Edelman R

    更新日期：1992-01-01 00:00:00

  • The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.

    abstract：:As part of safety monitoring during a group B meningococcal disease vaccination campaign in New Zealand, we examined the possible excess risk of vaccine-associated simple febrile seizures (SFS). We conducted a cohort analysis using data from active hospital-based surveillance in the South Auckland area and a national ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.12.001

    authors： Stehr-Green P,Radke S,Kieft C,Galloway Y,McNicholas A,Reid S

    更新日期：2008-02-06 00:00:00

  • Governments, off-patent vaccines, smallpox and universal childhood vaccination.

    abstract：:WHO is now celebrating more than 30 years of freedom from smallpox. What was originally seen as a victory over an ancient scourge can now be viewed as an epidemiologically driven programme to overcome governmental inertia and under-achievement in delivering an off-patent vaccine. Though efforts are accelerating global...

    journal_title：Vaccine

    pub_type： 社论

    doi：10.1016/j.vaccine.2009.08.006

    authors： Music S

    更新日期：2010-01-22 00:00:00

  • Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study.

    abstract：:Infection with influenza virus during pregnancy poses a significant risk of complications for both mother and fetus. During the H1N1 2009 pandemic, pregnant women constituted one of the priority groups for vaccination in many countries, creating a need for close monitoring of the safety of the vaccine in pregnant wome...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.04.114

    authors： Tavares F,Nazareth I,Monegal JS,Kolte I,Verstraeten T,Bauchau V

    更新日期：2011-08-26 00:00:00

  • Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.

    abstract：:Respiratory syncytial virus F-protein (RSV-F) is poorly expressed from DNA expression plasmids containing the wild type RSV-F open reading frame. By codon optimization, premature polyadenylation signals were deleted and a striking enhancement of RSV-F expression levels was achieved. Therefore, the immunogenicity and e...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.07.025

    authors： Ternette N,Tippler B,Uberla K,Grunwald T

    更新日期：2007-10-10 00:00:00

  • Murine helper T lymphocyte response to influenza virus: recognition of haemagglutinin by subtype-specific and cross-reactive T cell clones.

    abstract：:Helper T cel lines specific for influenza virus were established by continuous culture of Mem 71-Bel (H3) virus-immune spleen cells in the presence of virus and antigen-presenting cells and their specificity assessed in proliferation experiments. A line stimulated in vitro with Mem 71-Bel virus was able to proliferate...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(85)90118-5

    authors： Katz JM,Brown LE,Ffrench RA,White DO

    更新日期：1985-09-01 00:00:00

  • The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.

    abstract：:The efficacy of antibody immunity against Streptococcus pneumoniae stems from the ability of opsonic, serotype (ST)-specific antibodies to pneumococcal capsular polysaccharide (PPS) to facilitate killing of the homologous ST by host phagocytes. However, PPS-specific antibodies have been identified that are protective ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.08.061

    authors： Fabrizio K,Manix C,Tian H,van Rooijen N,Pirofski LA

    更新日期：2010-11-03 00:00:00

  • Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India.

    abstract：:This study investigates attitudes toward human papillomavirus (HPV) vaccination among parents of adolescent girls in Mysore, India. Seven focus group discussions were held among parents of adolescent girls stratified by sex, religion and region to explore attitudes about cervical cancer and HPV vaccination. The study ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.06.073

    authors： Madhivanan P,Krupp K,Yashodha MN,Marlow L,Klausner JD,Reingold AL

    更新日期：2009-08-20 00:00:00

  • Estimating the herd immunity effect of rotavirus vaccine.

    abstract：INTRODUCTION:Diarrhea is one of the leading causes of death in children under 5, and an estimated 39% of these deaths are attributable to rotavirus. Currently two live, oral rotavirus vaccines have been introduced on the market; however, the herd immunity effect associated with rotavirus vaccine has not yet been quanti...

    journal_title：Vaccine

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.vaccine.2015.06.064

    authors： Pollard SL,Malpica-Llanos T,Friberg IK,Fischer-Walker C,Ashraf S,Walker N

    更新日期：2015-07-31 00:00:00

  • Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein.

    abstract：:Effective immunoprophylaxis directed against the pre-erythrocytic stages of the malaria parasite requires a vaccine that can elicit humoral and cell mediated immunity in individuals of diverse genetic background. In order for a synthetic peptide malaria vaccine to meet these requirements, problems associated with gene...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00238-7

    authors： Nardin EH,Calvo-Calle JM,Oliveira GA,Clavijo P,Nussenzweig R,Simon R,Zeng W,Rose K

    更新日期：1998-04-01 00:00:00

  • A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations.

    abstract：AIMS:The study was designed to evaluate a novel cationic lipid DNA adjuvant (N3) and its function for HIV-1gp160/rev DNA plasmid delivered intranasally. The primary N3/HIV-DNA plasmid immunizations were boosted intranasally with a gp41 peptide in a anionic L3 adjuvant. This novel prime-boost strategy of mucosal immuniz...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.08.015

    authors： Hinkula J,Devito C,Zuber B,Benthin R,Ferreira D,Wahren B,Schröder U

    更新日期：2006-05-22 00:00:00

  • Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age.

    abstract：:The reactogenicity and immunogenicity of the administration of recombinant vaccine against hepatitis B simultaneously (but at separate sites) with diphtheria/tetanus/pertussis (DTP) and oral polio vaccines were examined. Six hundred and twenty-six children (group I) were given hepatitis B vaccine at 0, 2 and 6 months ...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0264-410x(95)00040-8

    authors： Aristegui J,Muñiz J,Pérez Legorburu A,Imaz M,Arrate JP,Suárez MD,Goiri MD

    更新日期：1995-08-01 00:00:00

  • The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.

    abstract：:We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune response generated against ED-B using the non-toxic and biodegradable adjuvant Montanide ISA 720/CpG with the response elic...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.11.010

    authors： Huijbers EJ,Femel J,Andersson K,Björkelund H,Hellman L,Olsson AK

    更新日期：2012-01-05 00:00:00

  • The risk factors of transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China.

    abstract：:We aimed to evaluate the present situation and possible risk factors of HBV transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China. Two hundred and twenty one HBsAg carrier mothers and 247 children born to them were final...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.09.031

    authors： Li F,Wang Q,Zhang L,Su H,Zhang J,Wang T,Huang D,Wu J,Yan Y,Fan D

    更新日期：2012-11-19 00:00:00

  • Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.

    abstract：:Liquid vaccine dosage forms have limited stability and require refrigeration during their manufacture, distribution and storage. In contrast, solid vaccine dosage forms, produced by for example spray drying, offer improved storage stability and reduced dependence on cold-chain facilities. This is advantageous for mass...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.04.055

    authors： Thakur A,Ingvarsson PT,Schmidt ST,Rose F,Andersen P,Christensen D,Foged C

    更新日期：2018-05-31 00:00:00

  • Detecting and preventing reversion to toxicity for a formaldehyde-treated C. difficile toxin B mutant.

    abstract：:The toxicity of Clostridium difficile large clostridial toxin B (TcdB) can be reduced by many orders of magnitude by a combination of targeted point mutations. However, a TcdB mutant with five point mutations (referred to herein as mTcdB) still has residual toxicity that can be detected in cell-based assays and in-viv...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.06.032

    authors： Wang B,Wang S,Rustandi RR,Wang F,Mensch CD,Hong L,Kristopeit A,Secore S,Dornadula G,Kanavage A,Heinrichs JH,Mach H,Blue JT,Thiriot DS

    更新日期：2015-01-01 00:00:00

  • Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells.

    abstract：BACKGROUND:Racial differences have been observed in the rate of bacterial infection and disease progression in HIV. Here, we evaluate racial differences in seasonal influenza vaccine responses. METHODS:16 healthy controls (9 Caucasians (CC) and 7 African Americans (AA)) and 26 antiretroviral therapy (ART)-treated avir...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.01.002

    authors： Ma P,Luo Z,Qian J,Yan Z,Zhang L,Martin L,Wang Z,Xia H,Yu F,Jiang W

    更新日期：2020-02-18 00:00:00

  • Homotypic and heterotypic immune responses to group A rotaviruses in parenterally immunized sheep.

    abstract：:Immune responses to human rotaviruses were investigated in sheep with a view to obtaining antibodies for passive immunotherapy of humans. Eighteen adult sheep with previous natural exposure to rotavirus serotypes G3 and G6 were immunized parenterally with purified preparations of either individual rotavirus serotypes ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(93)90027-u

    authors： Beards GM,King JA,Mazhar S,Landon J,Desselberger U

    更新日期：1993-01-01 00:00:00

  • Development of a recombinant vaccine against aerosolized plague.

    abstract：:Although few diseases have had a greater impact on human history, currently there is no vaccine available for protection against plague that is licensed by the Food and Drug Administration (FDA). DynPort Vaccine Company LLC, a CSC company (DVC), is managing the advanced development of a recombinant plague vaccine (rF1...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.01.071

    authors： Morris SR

    更新日期：2007-04-20 00:00:00

  • Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.

    abstract：:Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination aga...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.07.051

    authors： Gupta G,Giannino V,Rishi N,Glueck R

    更新日期：2016-09-07 00:00:00

  • Immune response of mice to immunization with subunit influenza A vaccine in DTP vaccine.

    abstract：:Experiments were carried out to examine the initial feasibility of immunizing infants and children with inactivated influenza virus vaccine combined with diphtheria-tetanus-pertussis (DTP) vaccine. Groups of mice were immunized with saline vaccine or vaccine mixed with DTP: three doses of vaccine were given 3 weeks ap...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)93310-6

    authors： Potter CW,Tamizifar H,Jennings R

    更新日期：1995-02-01 00:00:00

  • The use of sequence analysis of a feline calicivirus (FCV) hypervariable region in the epidemiological investigation of FCV related disease and vaccine failures.

    abstract：:A reverse transcriptase polymerase chain reaction (PCR) was used to amplify a 235 bp hypervariable region of the feline calicivirus (FCV) genome which encodes part of the capsid protein. Sequence from this region was used to compare viruses used in three attenuated vaccines to viruses isolated from vaccinated cats wit...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00059-5

    authors： Radford AD,Bennett M,McArdle F,Dawson S,Turner PC,Glenn MA,Gaskell RM

    更新日期：1997-08-01 00:00:00

  • The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.

    abstract：:Intranasal live attenuated influenza vaccine (LAIV) has potential for self-administration (SA) by adults and adolescents, which could save time and cost in mass vaccination settings. Participants in a study of LAIV in adults (n=4561) selected either SA or health care provider (HCP) administration and were followed for...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2012.12.028

    authors： Ambrose CS,Wu X

    更新日期：2013-01-30 00:00:00

  • A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

    abstract：:Sin Nombre virus (SNV; family Bunyaviridae, genus Hantavirus) causes a hemorrhagic fever known as hantavirus pulmonary syndrome (HPS) in North America. There have been approximately 200 fatal cases of HPS in the United States since 1993, predominantly in healthy working-age males (case fatality rate 35%). There are no...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.07.025

    authors： Hooper JW,Josleyn M,Ballantyne J,Brocato R

    更新日期：2013-09-13 00:00:00

  • Directed selection of amino acid changes in the influenza hemagglutinin and neuraminidase affecting protein antigenicity.

    abstract：:Influenza virus hemagglutinin (HA) and neuraminidase (NA) proteins elicit protective antibody responses and therefore, are used as targets for vaccination, especially the HA protein. However, these proteins are subject to antigenic drift, decreasing vaccine efficacy, and few to no studies have analyzed antigenic varia...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.09.005

    authors： DeDiego ML,Chiem K,Topham DJ

    更新日期：2018-10-15 00:00:00

  • Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.

    abstract：:Binding of antibodies to oligomeric envelope glycoprotein of R5-tropic primary isolates of human immunodeficiency virus type 1 (HIV-1) was studied by flow cytometry using sera from HIV-1 vaccine recipients and clade B and C HIV-1-infected patients, and monoclonal and polyclonal antibodies to neutralizing epitopes of H...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.07.013

    authors： Gorse GJ,Patel GB,Arbuckle JA,Belshe RB

    更新日期：2004-01-02 00:00:00

  • Protection against filarial infection by 45-49 kDa molecules of Brugia malayi via IFN-γ-mediated iNOS induction.

    abstract：:Nitric oxide (NO) mediated mechanisms have been implicated in killing of some life-stages of Brugia malayi/Wuchereria bancrofti and protect the host through type 1 responses and IFN-γ stimulated toxic mediators' release. However, the identity of NO stimulating molecules of the parasites is not known. Three predominant...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.11.041

    authors： Verma SK,Joseph SK,Verma R,Kushwaha V,Parmar N,Yadav PK,Thota JR,Kar S,Murthy PK

    更新日期：2015-01-15 00:00:00